Fulgent Genetics (FLGT) AI Stock Analysis

• Market Cap: $726.66M
• Dividend Yield: N/A
• Average Volume (3M): 216.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 4.31%
• EPS Growth: 69.57%
• Country: US
• Employees: 1,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.07
• Shares Outstanding: 30,609,043
• 10 Day Avg. Volume: 196,543
• 30 Day Avg. Volume: 216,030
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 1.05
• Enterprise Value/Gross Profit: 2.61
• Enterprise Value/Ebitda: -7.25
• 1Y Price Target: $25.33
• Price Target Upside: 6.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 61 Neutral
• Price Target: $25.00 ▲(5.31% Upside)

Fulgent Genetics' overall stock score reflects a mixed financial performance with strong technical momentum. The company's robust revenue growth and strategic expansions are positive, but profitability and valuation remain concerns. The earnings call provided a cautiously optimistic outlook, balancing the operational challenges.

Fulgent Genetics Business Overview & Revenue Model

Company Description

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

How the Company Makes Money

Fulgent Genetics generates revenue primarily through its genetic testing services. The company's revenue model is based on the fees charged for its diagnostic tests, which include both routine and custom genomic tests. Key revenue streams include individual tests for hereditary cancer, infectious diseases, and other genetic conditions, as well as partnerships with healthcare institutions and laboratories that utilize Fulgent's testing capabilities. Additionally, Fulgent has established collaborations with pharmaceutical companies and research institutions, which contribute to its earnings by providing specialized testing services and insights for clinical trials and drug development. The company's ability to innovate and adapt its testing offerings to meet the evolving needs of the healthcare market also plays a significant role in sustaining its revenue growth.

Fulgent Genetics Financial Statement Overview

Summary

Fulgent Genetics is facing financial challenges with declining profitability and cash flow issues, despite a strong balance sheet with low leverage. The company needs to address operational inefficiencies and improve revenue generation to stabilize its financial performance.

Income Statement

Fulgent Genetics has faced declining revenues and profitability in recent years. The TTM data indicates a negative EBIT and net profit margin, reflecting operational challenges. Despite a slight revenue growth in the TTM period compared to 2024, the company struggles to maintain profitability with gross and net profit margins significantly reduced from previous years.

Balance Sheet

The company maintains a strong equity position with a high equity ratio and low leverage, as indicated by a minimal debt-to-equity ratio. However, the return on equity has turned negative in recent periods, highlighting profitability issues. The overall financial stability remains robust due to substantial stockholders' equity and low debt.

Cash Flow

The cash flow statement shows a deterioration in free cash flow and operating cash flow in the TTM period, resulting in negative free cash flow growth. Operating cash flow to net income ratio is unfavorable due to negative net income. The company needs to improve cash flow generation to support operations and potential growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	303.22M	283.47M	289.21M	618.97M	992.58M	421.71M
Gross Profit	121.40M	107.22M	104.46M	366.90M	777.05M	331.90M
EBITDA	-43.78M	-48.99M	-46.55M	221.59M	686.96M	293.12M
Net Income	-51.02M	-42.71M	-167.82M	143.40M	507.36M	214.31M
Balance Sheet
Total Assets	1.20B	1.22B	1.24B	1.39B	1.28B	700.46M
Cash, Cash Equivalents and Short-Term Investments	292.93M	258.11M	424.15M	852.88M	935.55M	431.87M
Total Debt	7.39M	9.23M	15.25M	20.64M	21.28M	15.85M
Total Liabilities	88.20M	90.81M	102.04M	116.18M	112.84M	131.07M
Stockholders Equity	1.12B	1.13B	1.14B	1.27B	1.17B	569.39M
Cash Flow
Free Cash Flow	-59.95M	-19.25M	4.80M	234.75M	514.73M	104.12M
Operating Cash Flow	-25.09M	21.06M	27.00M	253.52M	538.58M	140.63M
Investing Cash Flow	62.66M	-58.35M	38.90M	-261.31M	-546.55M	-326.44M
Financing Cash Flow	-14.70M	-4.85M	-47.78M	-77.14M	85.39M	261.25M

Fulgent Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLGT, the sentiment is Positive. The current price of 23.74 is above the 20-day moving average (MA) of 22.98, above the 50-day MA of 22.35, and above the 200-day MA of 19.44, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 62.77 is Neutral, neither overbought nor oversold. The STOCH value of 58.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLGT.

Fulgent Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	―	$726.66M	―	-4.54%	―	4.31%	69.57%
CDNA	―	$796.81M	14.66	20.73%	―	14.72%	―
CSTL	―	$710.99M	―	-2.15%	―	20.40%	-165.41%
MYGN	―	$758.31M	―	-70.03%	―	3.83%	-137.31%
PSNL	―	$858.39M	―	-60.26%	―	0.36%	22.13%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	―	$542.43M	-4.43	-22.40%	―	13.17%	64.50%

Fulgent Genetics Corporate Events

Fulgent Genetics Presents Promising Phase 2 Trial Data

On October 20, 2025, Fulgent Genetics announced preliminary clinical data from its ongoing phase 2 trial of FID-007 in combination with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, showed promising anticancer efficacy and a favorable safety profile, suggesting potential advancements in oncology treatments. This development supports Fulgent’s mission to provide comprehensive cancer care solutions, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (FLGT) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.

Fulgent Genetics Reports Strong Core Revenue Growth

Fulgent Genetics, Inc. is a technology-based company specializing in laboratory services and therapeutic development, focusing on precision medicine and cancer treatment innovations. In its second quarter of 2025, Fulgent reported a core revenue growth of 16% year-over-year, reaching $81.7 million, and raised its full-year core revenue guidance to $320 million. Despite a GAAP loss of $19 million, the company achieved a non-GAAP income of $2.1 million, reflecting strategic financial management. Key highlights include a GAAP gross profit of $34.4 million with a gross margin of 42.1%, and a robust cash position of $777.5 million. The company also repurchased approximately 130,000 shares, indicating confidence in its growth trajectory. Looking ahead, Fulgent’s management remains optimistic about the second half of 2025, with expectations of continued revenue growth and strategic advancements in its laboratory and therapeutic development businesses.

Fulgent Genetics’ Earnings Call Highlights Growth and Optimism

Fulgent Genetics recently held its earnings call, revealing a generally positive sentiment despite some challenges. The company showcased impressive revenue growth, significant advancements in clinical trials, and strategic expansions, although these were tempered by increased operating expenses and a continued GAAP loss. Overall, the positive developments were prominent, painting an optimistic picture for the company’s future.

Fulgent Genetics Reports Q2 2025 Financial Results

On August 1, 2025, Fulgent Genetics announced its financial results for the second quarter of 2025, reporting a 16% year-over-year growth in core revenue to $81.7 million. Despite a GAAP loss of $19.0 million, the company raised its full-year core revenue guidance to $320 million, reflecting strong momentum and strategic progress in its laboratory services and therapeutic development businesses.

The most recent analyst rating on (FLGT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.